Melnick David A. 4
4 · Spero Therapeutics, Inc. · Filed Feb 3, 2020
Insider Transaction Report
Form 4
Melnick David A.
Chief Medical Officer
Transactions
- Award
Stock Option (Right to Buy)
2020-02-03+55,000→ 55,000 totalExercise: $9.34Exp: 2030-02-03→ Common Stock (55,000 underlying)
Footnotes (1)
- [F1]The shares underlying this option vest as to 25% on February 3, 2021, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.